PRODUCTS / PRODUCT PORTFOLIO

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.

123 4

Product	Indication	Dosage form	Strength
Fingolimod	Multiple sclerosis	Capsules	0.5 mg
Fluconazol	Antifungal	Hard capsules	50, 100, 150 and 200 mg
Fluconazol	Antifungal	Powder for oral suspension	200 mg/5ml and 50 mg/5ml
Hypromellose - Artificial tears	Dry eye	Eye drops, solution	0.5 ml (unit dose)
Imidapril *	Hypertension	Tablets	5, 10 and 20 mg
Ketorolac	Analgesic	Film-coated tablets	10 mg
Lacosamide	Epilepsy	Oral solution	10 mg/ml
Levetiracetam	Epilepsy	Film-coated tablets	250, 500, 750 and 1000 mg
Levetiracetam	Epilepsy	Granules for oral solution	250, 500, 750, 1000 and 1500 mg
Levetiracetam	Epilepsy	Oral solution	100 mg/ml
Levomethadone **	Pain, opiod maintenance therapy	Oral solution	5 mg/ml
Levomethadone **	Pain, opiod maintenance therapy	Oral drops, solution	5 mg/ml
Lisinopril	Hypertension	Tablets	5 and 20 mg
Lisinopril + HCTZ	Hypertension	Tablets	20/12.5 mg
Loratadine	Allergy	Film-coated tablets	10 mg
Memantine hydrochloride	Alzheimer's disease	Film-coated tablets	5, 10, 15 and 20 mg
Memantine hydrochloride	Alzheimer's disease	Oral solution	10 mg/ml
Methocarbamol	Muscle spasms, pain	Film-coated tablets	500, 750 and 1500 mg
Montelukast	Asthma, allergy	Chewable tablets	4 and 5 mg
Montelukast	Asthma, allergy	Film-coated tablets	10 mg

FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.